WHO WE ARE
Creative Medical Technology Holdings has developed/acquired a robust intellectual property (IP) portfolio related to the utilization of stem cells to improve patient lives in the areas of Urology, Neurology and Orthopedics.
This IP portfolio positions us at the forefront of the regenerative medicine industry (set to grow to $39Bn by 2023). We plan to commercialize these products on our own and in collaboration with strategic partners.
|Urology||US20180015127A1||Methods for Treatment of Premature Ovarian Failure and Ovarian Aging Using Regenerative Cells|
|Urology||US8372797B2||Treatment of Erectile Dysfunction by Stem Cell Therapy|
|Urology||US20180325959A1||Methods of Treating Erectile Dysfunction Using Regenerative Cells and Therapeutic Energy Treatments|
|Neuro/Oncology||US20190022147A1||Treatment of Glioma by Amniotic Fluid Stem Cells and Exosomes Derived Thereof|
|Neurology||US20180340145A1||Generation of Autologous Immune Modulatory Cells for Treatment of Neurological Conditions|
|Stem Cells||US7569385B2||Multipotent Amniotic Fetal Stem Cells|
|Orthopedics||US20180344899A1||Enhancement of Nucleus Pulposus Regeneration by Enhanced Perfusion of Perispinal Area by Combination Drug, Gene and Cellular Therapies|
|Orthopedics||US20180360882A1||Perispinal Perfusion by Administration of T Regulatory Cells Alone or in Combination with Angiogenic Cell Therapies|
|Orthopedics||US9598673B2||Treatment of Disc Degenerative Disease|
|Immunotherapy||US63123380||Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells|
|Immunotherapy||US62510,203.||Generation of Autologous Immune Modulatory Cells for Treatment of Neurological Conditions|
|Immunotherapy||US63132472||Treatment of Heart Failure and/or Post Infarct Pathological Remodeling by Ex Vivo Reprogrammed Immune Cells|
|Immunotherapy||US63138776||Treatment of Diabetes Using Immune Cells Reprogrammed Ex Vivo by Regenerative Cells|
|Immunotherapy||US63138576||Treatment of Liver Failure by Ex Vivo Reprogrammed Immune Cells|
|Immunotherapy||US63149671||Treatment of Chronic Rejection and Concurrent Induction of Transplantation Tolerance by Ex Vivo Altered Immune Cells|
Chief Executive Officer
Chief Financial Officer
Thomas Ichim PhD
Chief Scientific Officer
Thomas Ichim PhD
Amit Patel MS MD
Camillo Ricordi, MD
Is the Stacy Joy Goodman Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, and Microbiology and Immunology at the University of Miami (UM), Florida, where he serves as Director of the Diabetes Research Institute and the Cell Transplant Center.
Boris Reznik A.S. M.S. Ph.D. – SAB
Boris Reznik is the Chairman of Venvalo Group. During his career spanning four decades, Dr. Reznik founded and built technology companies into market leaders, managed high growth, profitable enterprises and successfully dealt with both Fortune 500 and emerging companies as clients and partners. He has been a lead or co-investor in multiple technology-based companies and has participated in many public and private fundings and mergers and acquisitions of technology-based companies, ranging from Millions to Billions.
Timothy Henry MD
Director of Cardiology, Christ Hospital, Cincinnati, OH. Dr. Henry’s experience also includes Director of Research at Minneapolis Heart Institute Foundation.
Santosh Kesari, MD, PhD
Director, Neuro-oncology; Chair and Professor, Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute
Regenerative Stem Cell Procedure for Treatment of Erectile Dysfunction in Men
Regenerative Stem Cell Procedure for Treatment of Female Sexual Dysfunction
Regenerative Stem Cell Procedure for Treatment of Degenerative Disc Disease
Amniotic Fluid Derived Stem Cells for Treatment of Stroke
Stem Cell Treatment for Premature Ovarian Failure
We work with Not For Profit and For Profit Organizations in the further development of our technologies. As related to Translational Projects we have defined policies and protocols in place that allows for indirect costs up to 25 percent of the direct costs. Direct costs + 25% of direct costs = Total project budget.
For inquiries, please contact the company: TimW@CreativeMedicalTechnology.com